NDA 218316 · Novo
Wegovy
Semaglutide · Oral
Last checked: Nov 19, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Dec 22, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
626
187 Phase 3, 161 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
4 products under this application
- WEGOVY · SEMAGLUTIDE 9MG · TABLET, ORAL · Prescription
- WEGOVY · SEMAGLUTIDE 1.5MG · TABLET, ORAL · Prescription
- WEGOVY · SEMAGLUTIDE 25MG · TABLET, ORAL · Prescription
- WEGOVY · SEMAGLUTIDE 4MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Semaglutide" as an intervention, any sponsor and status, largest first.
- A Study of Cardiovascular Events iN Diabetes PlusPivotal-lookingActive, not recruiting
University of OxfordAcademic, hospital or other
NCT05441267 · 21,296 participants · Start Mar 13, 2023 · Primary completion Aug 17, 2028
Drug: Semaglutide Oral Tablet; Placebo oral tablet · For: Diabetes Mellitus, Type 2
Sites: Oxford, United Kingdom
- Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or ObesityPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03574597 · 17,604 participants · Start Oct 24, 2018 · Primary completion Jun 21, 2023
Drug: Semaglutide; Placebo (semaglutide) · For: Overweight; Obesity
Sites: Birmingham, Alabama; Montgomery, Alabama; Glendale, Arizona · 833 sites in all
- A Heart Disease Study of Semaglutide in Patients With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03914326 · 9,651 participants · Start Jun 17, 2019 · Primary completion Aug 23, 2024
Drug: Semaglutide; Placebo (semaglutide) · For: Diabetes Mellitus, Type 2
Sites: Montgomery, Alabama; Little Rock, Arkansas; Searcy, Arkansas · 492 sites in all
- REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05669755 · 7,101 participants · Start Mar 1, 2023 · Primary completion Sep 1, 2027
Drug: Cagrilintide; Semaglutide and 1 more · For: Cardiovascular Disease
Sites: Birmingham, Alabama; Montgomery, Alabama; Scottsdale, Arizona · 633 sites in all
- PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesPivotal-lookingRecruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT05390892 · 6,000 participants (planned) · Start Sep 26, 2022 · Primary completion Mar 1, 2029
Drug: SGLT2 inhibitor; GLP-1 receptor agonist · For: Type2Diabetes; ASCVD
Sites: Huntsville, Alabama; Scottsdale, Arizona; Los Angeles, California · 36 sites in all
- A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney DiseasePivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03819153 · 3,533 participants · Start Jun 17, 2019 · Primary completion Jan 9, 2024
Drug: Semaglutide; Placebo (semaglutide) · For: Diabetes Mellitus, Type 2
Sites: Tuscumbia, Alabama; Chula Vista, California; Concord, California · 413 sites in all
- A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05567796 · 3,400 participants (planned) · Start Nov 1, 2022 · Primary completion Oct 30, 2024
Drug: Cagrilintide; Semaglutide and 2 more · For: Obesity
Sites: Birmingham, Alabama; Los Angeles, California; Aurora, Colorado · 256 sites in all
- Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01720446 · 3,297 participants · Start Feb 21, 2013 · Primary completion Mar 15, 2016
Drug: semaglutide; semaglutide and 1 more · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Chandler, Arizona; Anaheim, California · 253 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Wegovy (Semaglutide)
2024 spending
$301M
Beneficiaries
52,961
211,575 claims
Per beneficiary
$5,689
$602.09 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $199,774 |
| 2024 | $301,283,291 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.
McGuire DK, Marx N, Mulvagh SL, et al. · N Engl J Med 2025 · Multicenter Study, Randomized Controlled Trial
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH, Batterham RL, Calanna S, et al. · N Engl J Med 2021 · Multicenter Study, Randomized Controlled Trial
- Once-Weekly Semaglutide in Adolescents with Obesity.
Weghuber D, Barrett T, Barrientos-Pérez M, et al. · N Engl J Med 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
Rubino D, Abrahamsson N, Davies M, et al. · JAMA 2021 · Clinical Trial, Phase III, Comparative Study
- Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial.
Pratley RE, Tuttle KR, Rossing P, et al. · J Am Coll Cardiol 2024 · Randomized Controlled Trial, Multicenter Study
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
Wilding JPH, Batterham RL, Davies M, et al. · Diabetes Obes Metab 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Novo
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.